Recommendations for the Assessment of Adjuvants (Immunopotentiators)

  • D. E. S. Stewart-Tull
Part of the NATO ASI Series book series (NSSA, volume 179)


During the last decade there has been a significant expansion in the field of adjuvant research in many countries due, in part, to the success of the techniques of genetic manipulation, nucleotide sequencing and peptide synthesis. The potential exists to formulate totally synthetic vaccines (Jolivet et al, 1987) but it is also realized that the successful use of the new technologies will require a continued research effort to find adjuvant substances which do not have adverse biological properties (Vane and Cuatrecasas, 1984; Paquet et al, 1986; Stewart-Tull, 1988).


Aluminium Hydroxide Creatine Phosphokinase Adjuvant Arthritis Vaccine Antigen Muramyl Dipeptide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Allison, A.C., Byars, N.E. and Waters, R.V., 1986, “Advances in Carriers and Adjuvants for Veterinary Biologics”, R.M. Nervig. P.M. Gough, M.L. Kaeberle and C.A. Whetstone, eds., Iowa State University Press, Ames, Iowa.Google Scholar
  2. Byars, N.E. and Allison, A.C., 1987, Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunity, Vaccine, 5: 223.PubMedCrossRefGoogle Scholar
  3. Davenport, F.M., 1968, Seventeen years’ experience with mineral oil adjuvant influenza virus vaccines, Ann. Allergy, 26: 288.PubMedGoogle Scholar
  4. Edelman, R., 1980, Vaccine adjuvants, Rev.Infect.Dis., 2: 370.PubMedCrossRefGoogle Scholar
  5. Friedewald, W. F., 1944a, Adjuvants in immunization with influenza virus vaccines, J.Exp.Med., 80: 477.PubMedCrossRefGoogle Scholar
  6. Friedewald, W.F., 1944b, Enhancement of the immunizing capacity of influenza virus vaccines with adjuvants, Science, 99: 453.PubMedCrossRefGoogle Scholar
  7. Gisler, R.H., Dietrich, F.M., Baschang, G., Brownbill, A., Schumann, G., Staber, F.G., Tarcsay, L., Wachsmuth, E.D. and Dukor, P., 1979, “Drugs and Immune Responsiveness”, J.L. Turk and D. Parker, eds., Macmillan Press, London.Google Scholar
  8. Gray, J.E., Weaver, R.N., Moran, J. and Feenstra, E.S., 1974, The parenteral toxicity of clindamycin 2-phosphate in laboratory animals, Toxicol. Appl. Pharmacol., 27: 308.PubMedCrossRefGoogle Scholar
  9. Henle, W. and Henle, G., 1945, Effect of adjuvants on vaccination of human beings against influenza, Proc.Soc.Exptl.Biol.Med., 59: 179.Google Scholar
  10. Hughes, B.P., 1962, A method for the estimation of serum creatine kinase and its use in comparing creatine kinase and aldolase activity in normal and pathological sera, Clin.Chim.Acta, 7: 579.CrossRefGoogle Scholar
  11. Jolivet, M.E., Audibert, F.M., Gras-Masse, H., Tartar, A.L., Schlesinger, D.H., Wirtz, R. and Chedid, L.A., 1987, Induction of biologically active antibodies by a polyvalent synthetic vaccine constructed without carrier, Infect. Immun., 55: 1498.PubMedGoogle Scholar
  12. MacLennan, R., Schofield, F.D., Pittman, M., Hardegree, M.C. and Barile, M.F., 1965, Immunization against neonatal tetanus in New Guinea. Antitoxin response of pregnant women to adjuvant and plain toxoids, Bull.WHO, 32: 683.PubMedGoogle Scholar
  13. Mancini, G., Carbonara, A.O. and Heremans, J.F., 1965, Immunochemical quantitation of antigens by single radial immunodiffusion, Immunochemistry, 2: 235.PubMedCrossRefGoogle Scholar
  14. Miller, H.R.P., Woodbury, R.G., Huntley, J.F. and Newlands, G., 1983, Systemic release of mucosal mast-cell protease in primed rats challenged with Nippostrongylus brasiliensis, Immunology, 49: 471.Google Scholar
  15. Murray, R., Cohen, P. and Hardegree, M.C, 1972, Mineral oil adjuvants: biological and chemical studies, Ann. Allergy, 30: 146PubMedGoogle Scholar
  16. Ogonuki, H., Hashizume, S. and Abe, H., 1967, Histophathological tests of tissues in the sites of local reactions caused by the injection of oil-adjuvant cholera vaccine, Symp. Ser. Immunobiol. Stand., 6: 125.Google Scholar
  17. Paquet, A., Raines, K.M. and Brownback, P.C., 1986, Immunopotentiating activities of cell walls, peptidoglycans and teichoic acids from two strains of Listeria monocytogenes, Infect. Immun., 54: 170.Google Scholar
  18. Pearson, C.M. and Wood, F.D., 1959, Studies of polyarthritis and other lesions induced in rats by injection of mycobacterial adjuvant. I. General clinical and pathologic characteristics and some modifying factors, Arthritis and Rheumatism, 2: 440.CrossRefGoogle Scholar
  19. Rasanen, L., Mustikkamaki, U.P. and Arvilommi, H., 1982, Polyclonal response of human lymphocytes to bacterial cell walls, peptidoglycans and teichoic acids, Immunology, 46: 481.PubMedGoogle Scholar
  20. Rethy, L., 1965, The production and use of a stable aluminium hydroxide adsorbent, Prog.Immunobiol.Stand., 2: 80.Google Scholar
  21. Schmidt, G., 1967, The adjuvant effect of aluminium hydroxide in influenza vaccine. International Symposium on Adjuvants of Immunity, Utrecht, 1966, Sym.Ser.Immunobiol.Stand., 6: 275.Google Scholar
  22. Stewart-Tull, D.E.S., 1980, The immunological activities of bacterial peptidocylcans, Ann. Rev. Microbiol., 34: 311.CrossRefGoogle Scholar
  23. Stewart-Tull, D.E.S., 1983, Immunologically important constituents of mycobacteria: adjuvants, in: “Biology of Mycobacteria”, Vol. 2, C. Ratledge and J. Stanford, eds., Academic Press, London.Google Scholar
  24. Stewart-Tull, D.E.S., 1985a, Immunopotentiating conjugates, Vaccine, 3: 40.PubMedCrossRefGoogle Scholar
  25. Stewart-Tull, D.E.S., 1985b, Immunopotentiating activity of peptidoglycan and surface polymers, in: “Immunology of the Bacterial Cell Envelope”, D.E.S. Stewart-Tull and M. Davies, eds., John Wiley & Sons, Chichester.Google Scholar
  26. Stewart-Tull, D.E.S., 1988, Immunostimulation with peptidoglycan or its synthetic derivatives, Prog. Drug Res., 32, in press.Google Scholar
  27. Stewart-Tull, D.E.S. and Parant, M., 1986, Immunopotentiators in vaccines: a dream to a reality, Arm. Immunol. Hung., 26: 197.Google Scholar
  28. Vane, J. and Cuatrecasas, P., 1984, Genetic engineering and pharmaceuticals, Nature, 312: 303.PubMedCrossRefGoogle Scholar
  29. Waksman, B.H., Pearson, C.M. and Sharp. J.T., 1960, Studies of arthritis and other lesions induced in rats by injection of mycobacterial adjuvants. II. Evidence that the disease is a disseminated immunologic response to exogenous antigen, J. Immunol. 85: 403.PubMedGoogle Scholar
  30. Wardlaw, A.C., 1985, “Practical Statistics for Experimental Biologists”, John Wiley & Sons, Chichester.Google Scholar
  31. Waters, R.V., Terrell, T.G. and Jones, G.H., 1986, Uveitis induction in the rabbit by muramyl dipeptides, Infect.Immun., 51: 816.PubMedGoogle Scholar
  32. Weeke, B., Weeke, E. and Lowenstein, H., 1975, The adsorption of serum proteins to aluminium hydroxide gel examined by means of quantitative Immunoelectrophoresis, Scand. J. Immunol., 4: 149.CrossRefGoogle Scholar
  33. World Health Organization, 1976, Immunological adjuvants, Techn.Rep.Ser., 595: 3.Google Scholar

Copyright information

© Plenum Press, New York 1989

Authors and Affiliations

  • D. E. S. Stewart-Tull
    • 1
  1. 1.Microbiology DepartmentAlexander Stone Building Garscube EstateBearsden, GlasgowUK

Personalised recommendations